Balaji Amines Limited — Updates, 14-11-2024: Press Release

**Financial Highlights:** Balaji Amines reported a consolidated revenue of ₹356 Crore for Q2FY25, down from ₹393 Crore in Q1FY25. EBITDA improved to ₹70 Crore with a margin of 20%, up from 19% in the previous quarter. However, net profit saw a decrease to ₹41 Crore compared to ₹46 Crore in Q1, resulting in a diluted EPS of ₹12.65. For the half-year, revenue was ₹749 Crore, lower than ₹857 Crore year-on-year.

**Strategic Initiatives and Growth Drivers:** The company has successfully commenced Methyl Amines production at Unit IV, significantly boosting its annual installed capacity to 88,000 MT. New projects in Electronic Grade DMC, Propylene Glycol Pharma Grade, and Di Methyl Ether are on track for commissioning this financial year.

**Business Developments:** Balaji Amines is expanding its offerings with a new plant for N-(N-Butyl) Thiophosphoric Triamide (NBPT) and adding equipment to its existing DMC/PG plant to enhance production capabilities.

**Market Position and Competitive Advantage:** The firm stands out as a leading manufacturer in its sector, notably for Morpholine, holding BIS certification. This positions the company well for capturing growth opportunities amidst a challenging market.

**Investor Implications:** The recent expansion initiatives and focus on high-margin products enhance Balaji Amines' growth trajectory, offering a positive outlook for investors, particularly as demand in API and agrochemical sectors remains strong.